Skip to content
The Nexus
DossierENTITY

out-licensing deals

Coverage of out-licensing deals in the Nexus archive.

Earliest in view: Jun 29 · 08:30 UTCMost recent: Jun 29 · 08:30 UTC
Co-mentioned in this coverage
United Statesplace1Chinaplace1biotech sectortopic1pharma sectortopic1U.S. Food and Drug Administrationorganization1Pharmcubeorganization1intellectual propertytopic1
Recent coverage
  • BUSINESSJun 29 · 08:30 UTCSTAT NEWS
    Opinion: STAT+: The U.S.-China biotech crackdown may hurt the scientists America needs the most

    The article discusses concerns that the U.S.-China biotech crackdown could harm American scientists, as China's biotech sector grows, contributing 34% of global new drugs in clinical development and out-licensing deals reaching $137.7 billion by 2025. It highlights tensions over intellectual property fears and state-run companies in China.